No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Jacobio Pharmaceuticals Group Co., Ltd. is a clinical-stage pharmaceutical firm specializing in the proprietary discovery and development of oncology therapies. Its primary drug development initiatives feature two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors, JAB-3312 and JAB-3068, which are being investigated for esophageal cancer. Also in development is JAB-8263, a small molecule designed to inhibit BET family proteins that regulate MYC transcription, aiming to treat a range of cancers, alongside JAB-21822, an oral small molecule specifically targeting the mutant KRAS G12C protein. Jacobio is further advancing JAB-BX102, a humanized inhibitory antibody against human CD73, intended for treating PD-1 resistant cancers. Other pipeline assets include JAB-6343, an inhibitor targeting fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma exhibiting FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, which targets a tumor metabolic pathway for solid tumor treatment; and JAB-BX300, a molecular antibody designed to target the RAS pathway for pancreatic and other solid tumors with KRAS mutations. The company maintains a strategic partnership with AbbVie Ireland Unlimited Company for the development and commercialization of SHP2 inhibitors. Established in 2015, Jacobio Pharmaceuticals is headquartered in Beijing, China.
www.jacobiopharma.comNo one on the platform currently holds 1167.HK.
No tracked institution reports a position in 1167.HK as of their last filing.
No one on the platform has traded 1167.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | -66.5% | -36.0% | ||||
| Profit Margin % | -272.7% | -304.7% | ||||
| Free Cash Flow Margin % | -359.2% | -295.0% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $805M | +605.1% | $0.66 | $0.55–$0.77 | — | 2 |
| 2027 | $329M | -59.2% | $-0.03 | $-0.32–$0.26 | — | 2 |
| 2028 | $337M | +2.4% | $-0.14 | $-0.19–$-0.10 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-24 | $0.01 | $0.89 | +7612.3% |
| 2026-03-10 | $-0.01 | $-0.12 | -999.9% |
| 2025-08-29 | $-0.19 | $-0.09 | +52.9% |
| 2025-03-19 | $0.05 | $0.02 | -60.0% |
| 2024-08-30 | $-0.29 | $-0.24 | +18.5% |
| 2024-03-28 | $-0.30 | $-0.28 | +7.4% |
| 2023-08-30 | $-0.31 | $-0.24 | +24.1% |
| 2023-03-22 | $-0.32 | $-0.36 | -14.3% |
| $1.31 |
| +2.34% |
| $2.7B |
| — |
| 2158.HKYidu Tech Inc. | $3.53 | +0.57% | $3.6B | — |
| 2410.HKTYK Medicines, Inc | $3.07 | +2.85% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry